R&D Day

Watch our CEO, Laurent Levy, and leading medical experts discuss the latest developments in the fields of radiation oncology, immunotherapy and nanomedicine at our recent R&D Day in New York. Learn how the technology of NBTXR3 can bring new advancements in oncology treatment and provide hope for cancer patients worldwide.

INTRODUCTION TO SPEAKERS

An introduction to our expert KOLs and the agenda for Nanobiotix's 2018 R&D Day in New York. Speakers include: David Raben, MD – Radiation Oncologist & Professor at University of Colorado, Denver; Laurent Levy, PhD – CEO & Founder of Nanobiotix; Colette Shen, MD, PhD – Radiation Oncologist & Professor at University of North Carolina Chapel Hill; James Welsh, MD – Radiation Oncologist & Professor at University of Texas, MD Anderson Cancer Center; Tanguy Seiwert, MD – Medical Oncologist & Professor at University of Chicago.

RADIOTHERAPY: WHERE IS INNOVATION NEEDED?

Radiotherapy aims to deliver incredibly sophisticated radiation to kill a tumor, and at the same time spare healthy tissue so that the patient does not suffer harmful side effects. Nanobiotix’s technology has a physical, universal mode of action that is currently being researched in combination with radiation therapy. In video #2, Dr David Raben discusses where innovation is still needed in radiotherapy & how nanotechnology could change the treatment paradigm.

BIRTH OF NBTXR3

Laurent Levy examines the importance of asking different questions, and how this leads to disruptive healthcare. 20 years ago, he asked himself, “Can we influence a cell by impacting its physics at the subcellular level?” This video presents how NBTXR3’s technology came into being, and the developments of NBTXR3 in clinical trials.

CHALLENGES IN HEAD & NECK CANCER

Treatment of head and neck cancer is challenging due to the many critical organs in a small area and the impact of toxicity on quality of life. Can we use new technology to reduce radiation dosing and still get the same cure rates and reduce toxicity? Video #4, Dr. Colette Shen discusses the challenges in head & neck cancer, and how NBTXR3 is being studied as a potential combination treatment in this indication. Current data show an increased number of patients with a complete response to therapy when combined with NBTXR3 than with radiation alone.

WHAT LIES AHEAD FOR IMMUNO-ONCOLOGY

Many tumors are not adequately responsive to checkpoint inhibitors and other IO approaches. Can we use radiation and nanoparticles to stimulate an immune response against a tumor? Watch video #5 to hear Dr. James Welsh to learn what advances are being developed in immunooncology, radiotherapy and nanomedicine.

STUDY 1100: CAN WE TURN COLD TUMORS HOT?

Once in a while, we as researchers must try something new and has the potential to revolutionize the treatment landscape. The 1100 trial selects patients who have failed radiation, who are radioresistant and not likely to be cured, and patients who are non-responders to checkpoint inhibitors. Preclinical and clinical data suggest that NBTXR3 has the potential to turn CPI non-responders into responders, and that these nanoparticles help induce immunogenesis, turning “cold” tumors into “hot” ones, allowing the immune system to recognize the tumor and get equipped against it. Dr. Tanguy Seiwert maps out Nanobiotix’s Phase I/II 1100 trial studying the potential immunogenic effect of NBTXR3 in head & neck cancer and non-small cell lung cancer patients.

GROUP PANEL: THE DISRUPTIVE POTENTIAL OF NBTXR3

Listen to our group panel answer the audience’s questions and discuss the future of nanomedicine, immunotherapy and radiotherapy.
Français